SAFETY DATA SHEET
according to Regulation (EC) No. 1907/2006

Ezetimibe / Atorvastatin Formulation

Version 2.6 Revision Date: 09.04.2021 SDS Number: 26498-00016 Date of last issue: 16.10.2020
Date of first issue: 29.10.2014

SECTION 1: Identification of the substance/mixture and of the company/undertaking

1.1 Product identifier

Trade name: Ezetimibe / Atorvastatin Formulation

1.2 Relevant identified uses of the substance or mixture and uses advised against

Use of the Substance/Mixture: Pharmaceutical

1.3 Details of the supplier of the safety data sheet

Company: Organon & Co.
30 Hudson Street, 33nd floor
07302 Jersey City, New Jersey, U.S.A

Telephone: 551-430-6000

E-mail address of person responsible for the SDS: EHSSTEWARD@organon.com

1.4 Emergency telephone number

215-631-6999

SECTION 2: Hazards identification

2.1 Classification of the substance or mixture

Classification (REGULATION (EC) No 1272/2008)
Specific target organ toxicity - repeated exposure, Category 2
Long-term (chronic) aquatic hazard, Category 2

H373: May cause damage to organs through prolonged or repeated exposure.
H411: Toxic to aquatic life with long lasting effects.

2.2 Label elements

Labelling (REGULATION (EC) No 1272/2008)

Hazard pictograms:

Signal word: Warning

Hazard statements:

H373 May cause damage to organs through prolonged or repeated exposure.
H411 Toxic to aquatic life with long lasting effects.

Precautionary statements:

Prevention:
P260 Do not breathe dust.
P273 Avoid release to the environment.
Hazardous components which must be listed on the label:
Atorvastatin

2.3 Other hazards
This substance/mixture contains no components considered to be either persistent, bioaccumulative and toxic (PBT), or very persistent and very bioaccumulative (vPvB) at levels of 0.1% or higher.

Ecological information: The substance/mixture does not contain components considered to have endocrine disrupting properties according to REACH Article 57(f) or Commission Delegated regulation (EU) 2017/2100 or Commission Regulation (EU) 2018/605 at levels of 0.1% or higher.

Toxicological information: The substance/mixture does not contain components considered to have endocrine disrupting properties according to REACH Article 57(f) or Commission Delegated regulation (EU) 2017/2100 or Commission Regulation (EU) 2018/605 at levels of 0.1% or higher.

Dust contact with the eyes can lead to mechanical irritation.
Contact with dust can cause mechanical irritation or drying of the skin.
May form explosive dust-air mixture during processing, handling or other means.

SECTION 3: Composition/information on ingredients

3.2 Mixtures

<table>
<thead>
<tr>
<th>Components</th>
<th>CAS-No. EC-No. Index-No. Registration number</th>
<th>Classification</th>
<th>Concentration (% w/w)</th>
</tr>
</thead>
<tbody>
<tr>
<td>Atorvastatin</td>
<td>134523-03-8</td>
<td>STOT RE 2; H373 (Liver, muscle) Aquatic Chronic 2; H411</td>
<td>&gt;= 10 - &lt; 20</td>
</tr>
<tr>
<td>Ezetimibe</td>
<td>163222-33-1</td>
<td>Aquatic Chronic 1; H410 M-Factor (Chronic aquatic toxicity): 1</td>
<td>&gt;= 2.5 - &lt; 10</td>
</tr>
</tbody>
</table>

For explanation of abbreviations see section 16.

SECTION 4: First aid measures

4.1 Description of first aid measures
General advice: In the case of accident or if you feel unwell, seek medical advice immediately.
When symptoms persist or in all cases of doubt seek medical advice.

Protection of first-aiders: First Aid responders should pay attention to self-protection, and use the recommended personal protective equipment when the potential for exposure exists (see section 8).

If inhaled: If inhaled, remove to fresh air. Get medical attention if symptoms occur.

In case of skin contact: Wash with water and soap. Get medical attention if symptoms occur.

In case of eye contact: If in eyes, rinse well with water. Get medical attention if irritation develops and persists.

If swallowed: If swallowed, DO NOT induce vomiting. Get medical attention if symptoms occur. Rinse mouth thoroughly with water.

### 4.2 Most important symptoms and effects, both acute and delayed

Risks: May cause damage to organs through prolonged or repeated exposure.

Contact with dust can cause mechanical irritation or drying of the skin.

Dust contact with the eyes can lead to mechanical irritation.

### 4.3 Indication of any immediate medical attention and special treatment needed

Treatment: Treat symptomatically and supportively.

### SECTION 5: Firefighting measures

#### 5.1 Extinguishing media

Suitable extinguishing media: Water spray

Alcohol-resistant foam

Carbon dioxide (CO2)

Dry chemical

Unsuitable extinguishing media: None known.

#### 5.2 Special hazards arising from the substance or mixture

Specific hazards during firefighting: Avoid generating dust; fine dust dispersed in air in sufficient concentrations, and in the presence of an ignition source is a potential dust explosion hazard. Exposure to combustion products may be a hazard to health.

Hazardous combustion products: Carbon oxides

Nitrogen oxides (NOx)
5.3 Advice for firefighters

Special protective equipment for firefighters: In the event of fire, wear self-contained breathing apparatus. Use personal protective equipment.

Specific extinguishing methods: Use extinguishing measures that are appropriate to local circumstances and the surrounding environment. Use water spray to cool unopened containers. Remove undamaged containers from fire area if it is safe to do so. Evacuate area.

SECTION 6: Accidental release measures

6.1 Personal precautions, protective equipment and emergency procedures

Personal precautions: Use personal protective equipment. Follow safe handling advice (see section 7) and personal protective equipment recommendations (see section 8).

6.2 Environmental precautions

Environmental precautions: Avoid release to the environment. Prevent further leakage or spillage if safe to do so. Retain and dispose of contaminated wash water. Local authorities should be advised if significant spillages cannot be contained.

6.3 Methods and material for containment and cleaning up

Methods for cleaning up: Sweep up or vacuum up spillage and collect in suitable container for disposal. Avoid dispersal of dust in the air (i.e., clearing dust surfaces with compressed air). Dust deposits should not be allowed to accumulate on surfaces, as these may form an explosive mixture if they are released into the atmosphere in sufficient concentration. Local or national regulations may apply to releases and disposal of this material, as well as those materials and items employed in the cleanup of releases. You will need to determine which regulations are applicable. Sections 13 and 15 of this SDS provide information regarding certain local or national requirements.

6.4 Reference to other sections

See sections: 7, 8, 11, 12 and 13.

SECTION 7: Handling and storage

7.1 Precautions for safe handling

Technical measures: Static electricity may accumulate and ignite suspended dust...
causing an explosion.

Provide adequate precautions, such as electrical grounding and bonding, or inert atmospheres.

Local/Total ventilation: Use only with adequate ventilation.

Advice on safe handling: Do not breathe dust.
Do not swallow.
Avoid contact with eyes.
Avoid prolonged or repeated contact with skin.
Handle in accordance with good industrial hygiene and safety practice, based on the results of the workplace exposure assessment
Minimize dust generation and accumulation.
Keep container closed when not in use.
Keep away from heat and sources of ignition.
Take precautionary measures against static discharges.
Take care to prevent spills, waste and minimize release to the environment.

Hygiene measures: If exposure to chemical is likely during typical use, provide eye flushing systems and safety showers close to the working place. When using do not eat, drink or smoke. Wash contaminated clothing before re-use.
The effective operation of a facility should include review of engineering controls, proper personal protective equipment, appropriate degowning and decontamination procedures, industrial hygiene monitoring, medical surveillance and the use of administrative controls.

7.2 Conditions for safe storage, including any incompatibilities

Requirements for storage areas and containers: Keep in properly labelled containers. Store in accordance with the particular national regulations.

Advice on common storage: Do not store with the following product types:
Strong oxidizing agents

7.3 Specific end use(s)

Specific use(s): No data available

SECTION 8: Exposure controls/personal protection

8.1 Control parameters

<table>
<thead>
<tr>
<th>Components</th>
<th>CAS-No.</th>
<th>Value type (Form of exposure)</th>
<th>Control parameters</th>
<th>Basis</th>
</tr>
</thead>
<tbody>
<tr>
<td>Atorvastatin</td>
<td>134523-03-8</td>
<td>TWA</td>
<td>0.05 mg/m³ (OEB 3)</td>
<td>Internal</td>
</tr>
<tr>
<td></td>
<td></td>
<td>Wipe limit</td>
<td>0.5 mg/100 cm²</td>
<td>Internal</td>
</tr>
<tr>
<td>Ezetimibe</td>
<td>163222-33-1</td>
<td>TWA</td>
<td>25 µg/m³ (OEB 3)</td>
<td>Internal</td>
</tr>
<tr>
<td></td>
<td></td>
<td>Wipe limit</td>
<td>250 µg/100 cm²</td>
<td>Internal</td>
</tr>
</tbody>
</table>
8.2 Exposure controls

**Engineering measures**
All engineering controls should be implemented by facility design and operated in accordance with GMP principles to protect products, workers, and the environment. Containment technologies suitable for controlling compounds are required to control at source and to prevent migration of the compound to uncontrolled areas (e.g., open-face containment devices). Minimize open handling.

**Personal protective equipment**

- **Eye protection**: Wear safety glasses with side shields or goggles. If the work environment or activity involves dusty conditions, mists or aerosols, wear the appropriate goggles. Wear a faceshield or other full face protection if there is a potential for direct contact to the face with dusts, mists, or aerosols.

- **Hand protection**
  - Material: Chemical-resistant gloves
  - Remarks: Consider double gloving.

- **Skin and body protection**: Work uniform or laboratory coat. Additional body garments should be used based upon the task being performed (e.g., sleevelets, apron, gauntlets, disposable suits) to avoid exposed skin surfaces. Use appropriate degowning techniques to remove potentially contaminated clothing.

- **Respiratory protection**: If adequate local exhaust ventilation is not available or exposure assessment demonstrates exposures outside the recommended guidelines, use respiratory protection. Equipment should conform to NS EN 143
  - Filter type: Particulates type (P)

**SECTION 9: Physical and chemical properties**

**9.1 Information on basic physical and chemical properties**

- **Physical state**: powder
- **Colour**: off-white
- **Odour**: No data available
- **Odour Threshold**: No data available
- **Melting point/freezing point**: No data available
- **Initial boiling point and boiling range**: No data available
- **Flammability (solid, gas)**: May form explosive dust-air mixture during processing, handling or other means.
- **Flammability (liquids)**: No data available
- **Upper explosion limit / Upper flammability limit**: No data available
### SAFETY DATA SHEET
according to Regulation (EC) No. 1907/2006

**Ezetimibe / Atorvastatin Formulation**

<table>
<thead>
<tr>
<th>Version</th>
<th>Revision Date:</th>
<th>SDS Number:</th>
<th>Date of last issue:</th>
<th>Date of first issue:</th>
</tr>
</thead>
</table>

<table>
<thead>
<tr>
<th>Property</th>
<th>Value</th>
</tr>
</thead>
<tbody>
<tr>
<td>Lower explosion limit / Lower</td>
<td>No data available</td>
</tr>
<tr>
<td>flammability limit</td>
<td></td>
</tr>
<tr>
<td>Flash point</td>
<td>Not applicable</td>
</tr>
<tr>
<td>Auto-ignition temperature</td>
<td>No data available</td>
</tr>
<tr>
<td>Decomposition temperature</td>
<td>No data available</td>
</tr>
<tr>
<td>pH</td>
<td>No data available</td>
</tr>
<tr>
<td>Viscosity</td>
<td>No data available</td>
</tr>
<tr>
<td>Solubility(ies)</td>
<td></td>
</tr>
<tr>
<td>Water solubility</td>
<td>0,01 g/l</td>
</tr>
<tr>
<td>Partition coefficient: n-</td>
<td>No data available</td>
</tr>
<tr>
<td>octanol/water</td>
<td></td>
</tr>
<tr>
<td>Vapour pressure</td>
<td>No data available</td>
</tr>
<tr>
<td>Relative density</td>
<td>No data available</td>
</tr>
<tr>
<td>Density</td>
<td>No data available</td>
</tr>
<tr>
<td>Relative vapour density</td>
<td>No data available</td>
</tr>
<tr>
<td>Particle characteristics</td>
<td></td>
</tr>
<tr>
<td>Particle size</td>
<td>No data available</td>
</tr>
</tbody>
</table>

#### 9.2 Other information

<table>
<thead>
<tr>
<th>Property</th>
<th>Value</th>
</tr>
</thead>
<tbody>
<tr>
<td>Explosives</td>
<td>Not explosive</td>
</tr>
<tr>
<td>Oxidizing properties</td>
<td>The substance or mixture is not classified as oxidizing.</td>
</tr>
<tr>
<td>Evaporation rate</td>
<td>No data available</td>
</tr>
<tr>
<td>Molecular weight</td>
<td>No data available</td>
</tr>
</tbody>
</table>

#### SECTION 10: Stability and reactivity

**10.1 Reactivity**

Not classified as a reactivity hazard.

**10.2 Chemical stability**

Stable under normal conditions.

**10.3 Possibility of hazardous reactions**

<table>
<thead>
<tr>
<th>Hazardous reactions</th>
<th>May form explosive dust-air mixture during processing, handling or other means. Can react with strong oxidizing agents.</th>
</tr>
</thead>
</table>
10.4 Conditions to avoid
Conditions to avoid: Heat, flames and sparks. Avoid dust formation.

10.5 Incompatible materials
Materials to avoid: Oxidizing agents

10.6 Hazardous decomposition products
No hazardous decomposition products are known.

SECTION 11: Toxicological information

11.1 Information on hazard classes as defined in Regulation (EC) No 1272/2008

Information on likely routes of exposure:
- Inhalation
- Skin contact
- Ingestion
- Eye contact

Acute toxicity
Not classified based on available information.

Components:

Atorvastatin:
- Acute oral toxicity: LD50 (Rat, male and female): > 5.000 mg/kg
- LD50 (Mouse, male and female): > 5.000 mg/kg

Ezetimibe:
- Acute oral toxicity: LD50 (Rat): > 5.000 mg/kg
- LD50 (Mouse): > 5.000 mg/kg
- LD50 (Dog): > 3.000 mg/kg

Acute inhalation toxicity:
Remarks: No data available

Acute dermal toxicity:
Remarks: No data available

Acute toxicity (other routes of administration):
- LD50 (Rat): > 2.000 mg/kg
  Application Route: Intraperitoneal
- LD50 (Mouse): > 1.000 - < 2.000 mg/kg
  Application Route: Intraperitoneal

Skin corrosion/irritation
Not classified based on available information.

Components:

Atorvastatin:
Species: Rabbit
Result: No skin irritation

**Ezetimibe:***
Species: Rabbit
Result: No skin irritation

**Serious eye damage/eye irritation***
Not classified based on available information.

**Components:***

**Atorvastatin:***
Species: Rabbit
Method: Draize Test
Result: No eye irritation

**Ezetimibe:***
Species: Rabbit
Result: No eye irritation

**Respiratory or skin sensitisation***

**Skin sensitisation***
Not classified based on available information.

**Respiratory sensitisation***
Not classified based on available information.

**Components:***

**Atorvastatin:***
Test Type: Maximisation Test
Exposure routes: Skin contact
Species: Guinea pig
Result: negative

**Ezetimibe:***
Test Type: Maximisation Test
Species: Guinea pig
Result: negative

**Germ cell mutagenicity***
Not classified based on available information.

**Components:***

**Atorvastatin:***
Genotoxicity in vitro: Test Type: reverse mutation assay
Test system: Salmonella typhimurium
Result: negative
Test Type: reverse mutation assay
Test system: Escherichia coli
Result: negative

Test Type: In vitro mammalian cell gene mutation test
Test system: Chinese hamster lung cells
Result: negative

Test Type: sister chromatid exchange assay
Test system: Chinese hamster lung cells
Result: negative

Genotoxicity in vivo:
Test Type: In vivo micronucleus test
Species: Mouse
Cell type: Bone marrow
Application Route: Oral
Result: negative

Ezetimibe:
Genotoxicity in vitro:
Test Type: Bacterial reverse mutation assay (AMES)
Metabolic activation: with and without metabolic activation
Result: negative

Test Type: Chromosomal aberration
Test system: Human lymphocytes
Result: negative

Genotoxicity in vivo:
Test Type: Micronucleus test
Species: Mouse
Cell type: Bone marrow
Application Route: Oral
Result: negative

Carcinogenicity:
Not classified based on available information.

Components:

Atorvastatin:
Species: Mouse, male and female
Application Route: oral (gavage)
Exposure time: 2 Years
NOAEL: 200 mg/kg body weight
LOAEL: 400 mg/kg body weight
Result: negative
Target Organs: Liver

Species: Rat, female
Application Route: oral (gavage)
Exposure time: 2 Years
LOAEL: 100 mg/kg body weight
Target Organs: Musculo-skeletal system
Ezetimibe / Atorvastatin Formulation

Ezetimibe:
Species : Rat, female  
Application Route : oral (feed)  
Exposure time : 104 weeks  
Result : negative

Species : Rat, male  
Application Route : oral (feed)  
Exposure time : 104 weeks  
Result : negative

Species : Mouse  
Application Route : oral (feed)  
Exposure time : 104 weeks  
Result : negative

Reproductive toxicity
Not classified based on available information.

Components:

Atorvastatin:
Effects on fertility : Test Type: Fertility/early embryonic development  
Species: Rat, female  
Fertility: NOAEL: 225 mg/kg body weight  
Result: No effects on fertility

Test Type: Fertility/early embryonic development  
Species: Rat, male  
Fertility: NOAEL: 175 mg/kg body weight  
Result: No effects on fertility

Effects on foetal development : Species: Rat, female  
Developmental Toxicity: NOAEL: 20 mg/kg body weight  
Result: No teratogenic effects, Embryo-foetal toxicity  
Remarks: Maternal toxicity observed.

Species: Rabbit, female  
Application Route: Oral  
Developmental Toxicity: NOAEL: 100 mg/kg body weight  
Result: No embryo-foetal toxicity

Ezetimibe:
Effects on fertility : Test Type: Fertility/early embryonic development  
Species: Rat, male and female  
Fertility: NOAEL: > 1.000 mg/kg body weight  
Result: No effects on fertility, No fetotoxicity

Effects on foetal development : Test Type: Development  
Species: Rat  
Application Route: Oral
Developmental Toxicity: NOAEL: > 1.000 mg/kg body weight
Result: No adverse effects

Test Type: Development
Species: Rabbit
Application Route: Oral
Developmental Toxicity: NOAEL: > 1.000 mg/kg body weight
Result: No adverse effects

STOT - single exposure
Not classified based on available information.

STOT - repeated exposure
May cause damage to organs through prolonged or repeated exposure.

Components:

**Atorvastatin:**
<table>
<thead>
<tr>
<th>Exposure routes</th>
<th>Ingestion</th>
</tr>
</thead>
<tbody>
<tr>
<td>Target Organs</td>
<td>Liver, muscle</td>
</tr>
<tr>
<td>Assessment</td>
<td>May cause damage to organs through prolonged or repeated exposure</td>
</tr>
</tbody>
</table>

Repeated dose toxicity

Components:

**Atorvastatin:**
| Species           | Rat, male and female |
| LOAEL             | 70 mg/kg |
| Application Route | oral (gavage) |
| Exposure time     | 52 Weeks |
| Target Organs     | Liver |

| Species | Dog |
| LOAEL   | 10 mg/kg |
| Application Route | oral (gavage) |
| Exposure time | 104 Weeks |
| Target Organs | Liver |

**Ezetimibe:**
| Species | Dog |
| NOAEL   | 1.000 mg/kg |
| Application Route | Oral |
| Exposure time | 90 d |
| Remarks | No significant adverse effects were reported |

| Species | Rat |
| NOAEL   | 1.500 mg/kg |
| Application Route | Oral |
| Exposure time | 90 d |
| Remarks | No significant adverse effects were reported |
Species: Mouse  NOAEL: 500 mg/kg  Application Route: Oral  Exposure time: 90 d  Remarks: No significant adverse effects were reported

Species: Dog  NOAEL: 300 mg/kg  Application Route: Oral  Exposure time: 1 yr  Remarks: No significant adverse effects were reported

**Aspiration toxicity**
Not classified based on available information.

**Components:**

**Ezetimibe:**
Not applicable

**11.2 Information on other hazards**

**Endocrine disrupting properties**

**Product:**
Assessment: The substance/mixture does not contain components considered to have endocrine disrupting properties according to REACH Article 57(f) or Commission Delegated regulation (EU) 2017/2100 or Commission Regulation (EU) 2018/605 at levels of 0.1% or higher.

**Experience with human exposure**

**Components:**

**Atorvastatin:**
Ingestion: Symptoms: muscle pain, Fatigue, stomach discomfort, Abdominal pain, constipation, flatulence, liver function change

**Ezetimibe:**
Ingestion: Symptoms: Headache, Nausea, Vomiting, Diarrhoea, flatulence, muscle pain, upper respiratory tract infection, Back pain, joint pain

**SECTION 12: Ecological information**

**12.1 Toxicity**

**Components:**

**Atorvastatin:**
Toxicity to fish: LC50 (Pimephales promelas (fathead minnow)): > 92 mg/l  Exposure time: 96 h
Method: OECD Test Guideline 203

Toxicity to daphnia and other aquatic invertebrates: EC50 (Daphnia magna (Water flea)): 200 mg/l
Exposure time: 48 h
Method: OECD Test Guideline 202

Toxicity to algae/aquatic plants: EC50 (Pseudokirchneriella subcapitata (green algae)): 108 mg/l
Exposure time: 72 h
Method: OECD Test Guideline 201

NOEC (Pseudokirchneriella subcapitata (green algae)): 14 mg/l
Exposure time: 72 h
Method: OECD Test Guideline 201

Toxicity to microorganisms: EC50 : > 1.000 mg/l
Exposure time: 3 h
Test Type: Respiration inhibition

Toxicity to fish (Chronic toxicity): NOEC: 0,49 mg/l
Exposure time: 33 d
Species: Pimephales promelas (fathead minnow)
Method: OECD Test Guideline 210

Toxicity to daphnia and other aquatic invertebrates (Chronic toxicity): NOEC: 0,2 mg/l
Exposure time: 21 d
Species: Daphnia magna (Water flea)
Method: OECD Test Guideline 211

Ezetimibe:

Toxicity to fish: LC50 (Pimephales promelas (fathead minnow)): > 0,125 mg/l
Exposure time: 96 h
Method: OECD Test Guideline 203
Remarks: No toxicity at the limit of solubility

Toxicity to daphnia and other aquatic invertebrates: EC50 (Daphnia magna (Water flea)): > 4 mg/l
Exposure time: 48 h
Method: OECD Test Guideline 202
Remarks: No toxicity at the limit of solubility

Toxicity to algae/aquatic plants: EC50 (Pseudokirchneriella subcapitata (green algae)): > 0,317 mg/l
Exposure time: 96 h
Method: OECD Test Guideline 201
Remarks: No toxicity at the limit of solubility

NOEC (Pseudokirchneriella subcapitata (green algae)): 0,317 mg/l
Exposure time: 96 h
Method: OECD Test Guideline 201
Remarks: No toxicity at the limit of solubility
Toxicity to microorganisms : EC50: > 4,4 mg/l
Exposure time: 3 h
Test Type: Respiration inhibition
Method: OECD Test Guideline 209
Remarks: No toxicity at the limit of solubility

NOEC: 4,4 mg/l
Exposure time: 3 h
Test Type: Respiration inhibition
Method: OECD Test Guideline 209
Remarks: No toxicity at the limit of solubility

Toxicity to fish (Chronic toxicity): NOEC: 0,051 mg/l
Exposure time: 33 d
Species: Pimephales promelas (fathead minnow)
Method: OECD Test Guideline 210

NOEC: 4 mg/l
Exposure time: 7 d
Species: Cyprinodon variegatus (sheepshead minnow)
Remarks: No toxicity at the limit of solubility

Toxicity to daphnia and other aquatic invertebrates (Chronic toxicity): NOEC: 0,282 mg/l
Exposure time: 21 d
Species: Daphnia magna (Water flea)
Remarks: No toxicity at the limit of solubility

M-Factor (Chronic aquatic toxicity): 1

12.2 Persistence and degradability

Components:

Atorvastatin:
Biodegradability: Result: Not readily biodegradable.
Biodegradation: 7,7 %
Exposure time: 28 d
Method: OECD Test Guideline 314

Ezetimibe:
Biodegradability: Result: Not readily biodegradable.
Biodegradation: 6,8 %
Exposure time: 28 d

Stability in water: Hydrolysis: 50 % (4,5 d)
Method: OECD Test Guideline 111

12.3 Bioaccumulative potential

Components:

Atorvastatin:
Partition coefficient: n-
log Pow: 1,62
Ezetimibe / Atorvastatin Formulation

octanol/water

**Ezetimibe:**

Bioaccumulation:
- Species: Lepomis macrochirus (Bluegill sunfish)
- Exposure time: 97 d
- Bioconcentration factor (BCF): 173
- Method: OECD Test Guideline 305

Partition coefficient: n-octanol/water:
- log Pow: 4.36

12.4 Mobility in soil

**Components:**

**Atorvastatin:**

Distribution among environmental compartments:
- log Koc: 2.84

**Ezetimibe:**

Distribution among environmental compartments:
- log Koc: 4.35
  - Method: OECD Test Guideline 106

12.5 Results of PBT and vPvB assessment

**Product:**

Assessment:
- This substance/mixture contains no components considered to be either persistent, bioaccumulative and toxic (PBT), or very persistent and very bioaccumulative (vPvB) at levels of 0.1% or higher.

12.6 Other adverse effects

**Product:**

Endocrine disrupting potential:
- The substance/mixture does not contain components considered to have endocrine disrupting properties according to REACH Article 57(f) or Commission Delegated regulation (EU) 2017/2100 or Commission Regulation (EU) 2018/605 at levels of 0.1% or higher.

SECTION 13: Disposal considerations

13.1 Waste treatment methods

**Product:**

Dispose of in accordance with local regulations.
According to the European Waste Catalogue, Waste Codes are not product specific, but application specific.
Waste codes should be assigned by the user, preferably in discussion with the waste disposal authorities.

**Contaminated packaging:**

Empty containers should be taken to an approved waste handling site for recycling or disposal.
If not otherwise specified: Dispose of as unused product.
SECTION 14: Transport information

14.1 UN number or ID number

<table>
<thead>
<tr>
<th></th>
<th>ADN</th>
<th>ADR</th>
<th>RID</th>
<th>IMDG</th>
<th>IATA</th>
</tr>
</thead>
<tbody>
<tr>
<td>ADN</td>
<td>UN 3077</td>
<td>UN 3077</td>
<td>UN 3077</td>
<td>UN 3077</td>
<td>UN 3077</td>
</tr>
</tbody>
</table>

14.2 UN proper shipping name

<table>
<thead>
<tr>
<th></th>
<th>ADN</th>
<th>ADR</th>
<th>RID</th>
<th>IMDG</th>
<th>IATA</th>
</tr>
</thead>
<tbody>
<tr>
<td>ADN</td>
<td>ENVIRONMENTALLY HAZARDOUS SUBSTANCE, SOLID, N.O.S. (Ezetimibe, Atorvastatin)</td>
<td>ENVIRONMENTALLY HAZARDOUS SUBSTANCE, SOLID, N.O.S. (Ezetimibe, Atorvastatin)</td>
<td>ENVIRONMENTALLY HAZARDOUS SUBSTANCE, SOLID, N.O.S. (Ezetimibe, Atorvastatin)</td>
<td>ENVIRONMENTALLY HAZARDOUS SUBSTANCE, SOLID, N.O.S. (Ezetimibe, Atorvastatin)</td>
<td>Environmentally hazardous substance, solid, n.o.s. (Ezetimibe, Atorvastatin)</td>
</tr>
</tbody>
</table>

14.3 Transport hazard class(es)

<table>
<thead>
<tr>
<th></th>
<th>ADN</th>
<th>ADR</th>
<th>RID</th>
<th>IMDG</th>
<th>IATA</th>
</tr>
</thead>
<tbody>
<tr>
<td>ADN</td>
<td>9</td>
<td>9</td>
<td>9</td>
<td>9</td>
<td>9</td>
</tr>
</tbody>
</table>

14.4 Packing group

<table>
<thead>
<tr>
<th></th>
<th>ADN</th>
<th>ADR</th>
</tr>
</thead>
<tbody>
<tr>
<td>ADN</td>
<td>Packing group: III</td>
<td>Packing group: III</td>
</tr>
<tr>
<td></td>
<td>Classification Code: M7</td>
<td>Classification Code: M7</td>
</tr>
<tr>
<td></td>
<td>Hazard Identification Number: 90</td>
<td>Hazard Identification Number: 90</td>
</tr>
<tr>
<td></td>
<td>Labels: 9</td>
<td>Labels: 9</td>
</tr>
<tr>
<td>ADN</td>
<td>Tunnel restriction code: (-)</td>
<td>Tunnel restriction code: (-)</td>
</tr>
</tbody>
</table>
SAFETY DATA SHEET
according to Regulation (EC) No. 1907/2006

Ezetimibe / Atorvastatin Formulation

Version 2.6 Revision Date: 09.04.2021 SDS Number: 26498-00016 Date of last issue: 16.10.2020
Date of first issue: 29.10.2014

RID
Packing group : III
Classification Code : M7
Hazard Identification Number : 90
Labels : 9

IMDG
Packing group : III
Labels : 9
EmS Code : F-A, S-F

IATA (Cargo)
Packing instruction (cargo aircraft) : 956
Packing instruction (LQ) : Y956
Packing group : III
Labels : Miscellaneous

IATA (Passenger)
Packing instruction (passenger aircraft) : 956
Packing instruction (LQ) : Y956
Packing group : III
Labels : Miscellaneous

14.5 Environmental hazards

ADN
Environmentally hazardous : yes

ADR
Environmentally hazardous : yes

RID
Environmentally hazardous : yes

IMDG
Marine pollutant : yes

IATA (Passenger)
Environmentally hazardous : yes

IATA (Cargo)
Environmentally hazardous : yes

14.6 Special precautions for user
The transport classification(s) provided herein are for informational purposes only, and solely based upon the properties of the unpackaged material as it is described within this Safety Data Sheet. Transportation classifications may vary by mode of transportation, package sizes, and variations in regional or country regulations.

14.7 Maritime transport in bulk according to IMO instruments
Remarks : Not applicable for product as supplied.

SECTION 15: Regulatory information

15.1 Safety, health and environmental regulations/legislation specific for the substance or mixture
REACH - Restrictions on the manufacture, placing on the market and use of certain dangerous substances, preparations and articles (Annex XVII) : Not applicable
REACH - Candidate List of Substances of Very High Concern for Authorisation (Article 59). : Not applicable
REACH - List of substances subject to authorisation (Annex XIV) : Not applicable
Regulation (EC) No 1005/2009 on substances that deplete the ozone layer : Not applicable
Regulation (EU) 2019/1021 on persistent organic pollutants (recast) : Not applicable
Regulation (EC) No 649/2012 of the European Parliament and the Council concerning the export and import of dangerous chemicals : Not applicable

Other regulations:
Young people under the age of 18 are not allowed to use or be exposed to the product professionally. Young people above the age of 15 are, however, except from this rule if the product is a necessary part of their education.

The components of this product are reported in the following inventories:
AICS : not determined
DSL : not determined
IECSC : not determined

15.2 Chemical safety assessment
A Chemical Safety Assessment has not been carried out.

SECTION 16: Other information
Other information : Items where changes have been made to the previous version are highlighted in the body of this document by two vertical lines.

Full text of H-Stations
H373 : May cause damage to organs through prolonged or repeated exposure if swallowed.
H410 : Very toxic to aquatic life with long lasting effects.
H411 : Toxic to aquatic life with long lasting effects.

Full text of other abbreviations
Aquatic Chronic : Long-term (chronic) aquatic hazard
STOT RE : Specific target organ toxicity - repeated exposure

ADN - European Agreement concerning the International Carriage of Dangerous Goods by Inland Waterways; ADR - European Agreement concerning the International Carriage of Dangerous Goods by Road; AIIC - Australian Inventory of Industrial Chemicals; ASTM - American Society for
Ezetimibe / Atorvastatin Formulation

Further information

Classification of the mixture:
STOT RE 2 H373 Calculation method
Aquatic Chronic 2 H411 Calculation method

The information provided in this Safety Data Sheet is correct to the best of our knowledge, information and belief at the date of its publication. The information is designed only as a guidance for safe handling, use, processing, storage, transportation, disposal and release and shall not be considered a warranty or quality specification of any type. The information provided relates only to the specific material identified at the top of this SDS and may not be valid when the SDS material is used in combination with any other materials or in any process, unless specified in the text. Material users should review the information and recommendations in the specific context of their intended manner of handling, use, processing and storage, including an assessment of the appropriateness of the SDS material in the user’s end product, if applicable.